355 related articles for article (PubMed ID: 29186084)
1. Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.
Med Lett Drugs Ther; 2017 Dec; 59(1535):198-200. PubMed ID: 29186084
[No Abstract] [Full Text] [Related]
2. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
[TBL] [Abstract][Full Text] [Related]
3. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
[TBL] [Abstract][Full Text] [Related]
4. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
Tanner CM; Pahwa R; Hauser RA; Oertel WH; Isaacson SH; Jankovic J; Johnson R; Chernick D; Hubble J
J Parkinsons Dis; 2020; 10(2):543-558. PubMed ID: 31929122
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
Hauser RA; Kremens DE; Elmer LW; Kreitzman DL; Walsh RR; Johnson R; Howard R; Nguyen JT; Patni R
J Parkinsons Dis; 2019; 9(3):591-600. PubMed ID: 31081793
[TBL] [Abstract][Full Text] [Related]
6. Amantadine Extended-Release (GOCOVRI
Paik J; Keam SJ
CNS Drugs; 2018 Aug; 32(8):797-806. PubMed ID: 30088203
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis.
Pajo AT; Espiritu AI; Jamora RDG
Neurodegener Dis Manag; 2019 Aug; 9(4):205-215. PubMed ID: 31392922
[No Abstract] [Full Text] [Related]
8. Renaissance of amantadine in the treatment of Parkinson's disease.
Blanchet PJ; Metman LV; Chase TN
Adv Neurol; 2003; 91():251-7. PubMed ID: 12442683
[No Abstract] [Full Text] [Related]
9. The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.
Elkurd MT; Bahroo LB; Pahwa R
Neurodegener Dis Manag; 2018 Apr; 8(2):73-80. PubMed ID: 29564954
[TBL] [Abstract][Full Text] [Related]
10. Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
Elmer LW; Juncos JL; Singer C; Truong DD; Criswell SR; Parashos S; Felt L; Johnson R; Patni R
CNS Drugs; 2018 Apr; 32(4):387-398. PubMed ID: 29532440
[TBL] [Abstract][Full Text] [Related]
11. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
Snow BJ; Macdonald L; Mcauley D; Wallis W
Clin Neuropharmacol; 2000; 23(2):82-5. PubMed ID: 10803797
[TBL] [Abstract][Full Text] [Related]
12. Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
Furukawa Y; Filiano JJ; Kish SJ
Mov Disord; 2004 Oct; 19(10):1256-8. PubMed ID: 15389992
[TBL] [Abstract][Full Text] [Related]
13. Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
Dashtipour K; Tafreshi AR; Pahwa R; Lyons KE
Expert Rev Neurother; 2019 Apr; 19(4):293-299. PubMed ID: 30892103
[TBL] [Abstract][Full Text] [Related]
14. Current treatment and future prospects of dopa-induced dyskinesias.
Mazzucchi S; Frosini D; Bonuccelli U; Ceravolo R
Drugs Today (Barc); 2015 May; 51(5):315-29. PubMed ID: 26097904
[TBL] [Abstract][Full Text] [Related]
15. Rating scales for dyskinesias in Parkinson's disease.
Goetz CG
Mov Disord; 1999; 14 Suppl 1():48-53. PubMed ID: 10493403
[No Abstract] [Full Text] [Related]
16. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
[TBL] [Abstract][Full Text] [Related]
17. [Dyskinesia in Parkinson's disease: an update on new neuroimaging methods and treatment possibilities].
Thomsen BL; Herz DM; Siebner HR; Løkkegaard A
Ugeskr Laeger; 2017 Mar; 179(10):. PubMed ID: 28263159
[TBL] [Abstract][Full Text] [Related]
18. GOCOVRI
Müller T
Neurodegener Dis Manag; 2022 Feb; 12(1):15-28. PubMed ID: 34918543
[TBL] [Abstract][Full Text] [Related]
19. Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease?
Marmol S; Feldman M; Singer C; Margolesky J
CNS Drugs; 2021 Nov; 35(11):1141-1152. PubMed ID: 34648150
[TBL] [Abstract][Full Text] [Related]
20. Amantadine's role in the treatment of levodopa-induced dyskinesia.
Rodnitzky RL; Narayanan NS
Neurology; 2014 Jan; 82(4):288-9. PubMed ID: 24371305
[No Abstract] [Full Text] [Related]
[Next] [New Search]
